Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
17 juil. 2024 08h00 HE
|
Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08 juil. 2024 09h00 HE
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
17 juin 2024 09h00 HE
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
11 juin 2024 09h00 HE
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Longeveron® to Attend BIO International Convention 2024
28 mai 2024 08h05 HE
|
Longeveron
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
18 avr. 2024 16h05 HE
|
Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
15 avr. 2024 08h30 HE
|
Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Announces Closing of $5.2 Million Public Offering
11 avr. 2024 17h17 HE
|
Longeveron
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.
Longeveron Announces Pricing of $5.25 Million Public Offering
08 avr. 2024 14h15 HE
|
Longeveron
Longeveron prices $5.15 million public offering with certain board member and insider participation.